Innovative topical therapy for neurofibromatosis type 1 has positive phase 2 clinical results

On May 26, 2021, NFlection Therapeutics announced that its topical NFX-179 gel has achieved positive results in a phase 2a clinical trial for the treatment of neurofibromatosis type 1 (NF1) patients.

NFX-179 gel is designed to deliver a MEK inhibitor that is easily metabolically degraded to tumors by topical application on the skin surface to inhibit the excessive activation of the Ras/Raf/MEK/ERK pathway in these tumors.

In this multicenter, randomized double-blind, parallel grouping, placebo-controlled Phase 2a clinical trial, 48 patients were randomized to receive 0.

The test results show that, compared with the control group, 0.

In terms of safety and tolerance, NFX-179 gel is well tolerated.

Cutaneous neurofibromas are tumors that grow from small nerves in or under the skin.

Note: The original text has been deleted

Reference materials:

[1] NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial.